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Abstract
Background—Up to 50% of patients fail to meet ST-segment elevation myocardial infarction 
(STEMI) guideline goals recommending a first-medical-contact (FMC)-to-device time of <90 
minutes for patients directly presenting to percutaneous coronary intervention (PCI)-capable 
hospitals and <120 minutes for transferred patients. We sought to increase the proportion of 
patients treated within guideline goals by organizing coordinated regional reperfusion plans.
Methods—We established leadership teams, coordinated protocols, and provided regular 
feedback for 484 hospitals and 1253 emergency medical service (EMS) agencies in 16 regions 
across the United States.
Results—Between July 2012 and December 2013, 23,809 patients presented with acute STEMI 
(direct to PCI hospital: 11,765 EMS-transported and 6502 self-transported; transferred: 5542). 
EMS-transported patients differed from self-transported patients in symptom onset to FMC time 
(median: 47 versus 114 minutes), incidence of cardiac arrest (10% versus 3%), shock on 
admission (11% versus 3%), and in-hospital mortality (8% versus 3%) (p<0.001 for all 
comparisons). There was a significant increase in the proportion of patients meeting guideline 
goals of FMC-to-device time, including those directly presenting via EMS (50% to 55%; p<0.001) 
and transferred patients (44% to 48%; p=0.002). Despite regional variability, the greatest gains 
occurred among patients in the 5 most-improved regions, increasing from 45% to 57% (direct 
EMS; p<0.001), and 38% to 50% (transfers; p<0.001).
Conclusions—This Mission: Lifeline™ STEMI Systems Accelerator demonstration project 
represents the largest national effort to organize regional STEMI care. By focusing on FMC-to-
device time, coordinated treatment protocols, and regional data collection and reporting, we were 
able to significantly increase the proportion of patients treated within guideline goals.
Keywords
myocardial infarction; catheterization; reperfusion; survival
INTRODUCTION
Rapid coronary artery reperfusion is the foundation of treatment for acute ST-segment 
elevation myocardial infarction (STEMI) to improve survival. Based upon randomized trial 
data, national guidelines call for primary percutaneous coronary intervention (PCI) within 
90 minutes of paramedic arrival for patients who call 911 and are transferred directly to a 
hospital offering PCI (PCI-capable), and within 120 minutes of first medical contact (FMC) 
for patients requiring inter-hospital transfer.1,2 Despite 2 decades of evidence and 7 years 
since these guidelines were introduced, approximately 30% to 50% of patients fail to meet 
these standards.3–6 Considering that the number of PCI-capable hospitals increased by 
almost 50% and that 90% of Americans live within 60 minutes of a PCI-capable facility, 
inadequate access cannot entirely explain these systematic failures.7–10 Rather, the challenge 
lies within a highly fragmented health system comprising approximately 4750 acute care 
hospitals and more than 15,000 emergency medical service (EMS) agencies in the United 
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States. The challenge is further exacerbated by structural barriers that hinder coordination 
between EMS providers and hospitals, as well as competition among hospitals and physician 
groups. Such fragmentation has hindered the development of coordinated treatment plans 
and procedures, common data collection and feedback systems, and systematic approaches 
to accurately identify and direct STEMI patients to nearby catheterization laboratories for 
timely coronary intervention.11
Building upon successful efforts in organizing STEMI reperfusion systems on a regional 
basis, we developed a demonstration project designed to implement coordinated care in 
selected major metropolitan regions in the United States.12,13 Our hypothesis was that by 
organizing leadership, data collection, common protocols, and ongoing data review with 
timely feedback, we could increase the percentage of patients receiving primary PCI within 
guideline goals. Our intervention was based upon Mission: Lifeline™ established 
approaches and supported by a national faculty highly experienced in organizing regional 
STEMI care.
METHODS
The STEMI Systems Accelerator project intervention was organized and executed between 
March 2012 and July 2014 (Supplemental Figure 1). Among 21 regions that applied for 
participation in the project, 16 met enrollment criteria by the baseline data-collection quarter 
and were included. These criteria included the following: 1) 70% of PCI hospitals in the 
region were participating in the National Cardiovascular Data Registry’s ACTION 
Registry®-Get With The Guidelines™ (AR-G) program, 2) there was defined organization 
of regional leadership, 3) common protocols were established for the diagnosis and 
treatment of STEMI patients presenting to EMS personnel or hospitals lacking PCI facilities 
(PCI non-capable), 4) there was agreement to enter patients into the AR-G for 6 consecutive 
quarters, and 5) regional leadership participated in a 2-day national training session directed 
by study faculty reviewing current evidence, guidelines, and approaches to regional STEMI 
care.
Project initiation was conducted on a rolling basis over 6 months, and each region specified 
a quarter (quarters 3 or 4, 2012; or quarter 1, 2013) as the baseline from which to assess 
subsequent temporal trends in outcomes. Following hospital enrollment in the AR-G and the 
training of leadership, each region established common protocols as outlined above, 
implemented the protocols, and conducted ongoing measurement and feedback on 
performance that was reflected in quarterly hospital letter-coded regional STEMI treatment 
reports. These protocols were guided by local experts, resources, and practices, and included 
common criteria for establishing the diagnosis of STEMI, activating a catheterization 
laboratory with a single phone or radio call, treating the patient with simple initial regimens, 
and transporting the patient by pre-identified mechanisms. In each region, 2 project faculty 
members, including a cardiology or emergency medicine physician and a regional 
coordinator, conducted a launch meeting in collaboration with regional leadership.14 These 
meetings reviewed the principles of STEMI diagnosis and treatment, current national 
guidelines, and regional models for STEMI care, as well as case studies specific to each 
region for patients presenting to EMS providers and patients requiring hospital transfer.
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At each meeting, an EMS “wish list” was presented to encourage participating hospitals to 
support the needs of local providers. This list was a compilation of hospital requests by 
regional EMS leadership in order to facilitate diagnosis and treatment, and included requests 
such as activating the catheterization laboratory upon EMS call. In order to change the 
standard of care and create sustainable systems, we relied on local and regional mechanisms 
for protocol implementation, such as EMS annual training sessions or state-approved 
treatment protocols.
Statistical Analysis
The current study presents the primary outcomes and temporal trends over the 24 months 
after initiation of the STEMI Systems Accelerator project. The pre-specified primary 
outcome was the change in the percentage of patients meeting guideline goals over 6 
quarters (post-baseline quarter). Descriptive statistics for continuous and categorical 
variables were described as medians (quartiles) and numbers (percentages), respectively. 
Patient characteristics and process measures were compared by use of the Wilcoxon rank-
sum test for 2-group comparisons (the Kruskal-Wallis test was used for comparisons of more 
than 2 groups) for continuous variables and Pearson’s chi-square or Fisher exact tests, as 
appropriate for categorical variables. The Cochran-Armitage test for trend was used to assess 
changes in rates over time. The relationship between emergency department (ED) dwell time
—defined as the period from ED arrival to cardiac catheterization laboratory arrival—and 
in-hospital mortality was assessed using logistic regression modeling. The rolling 12-month 
(4 quarters) moving-average of in-hospital mortality for STEMI Systems Accelerator 
hospitals versus the AR-G registry hospitals were presented graphically.
All statistical tests were conducted at the 0.05 significance level. All patients with ischemic 
symptoms lasting >10 minutes within 12 hours before arrival and an electrocardiogram 
(ECG) with diagnostic ST-segment elevation were included in the analyses. In cases where 
the first ECG did not have diagnostic ST-segment elevation, door or FMC time was reset to 
the first diagnostic ECG. Statistical analyses were performed with SAS version 9.3 (SAS 
Institute Inc, Cary, NC). The project was reviewed by the Duke Institutional Review Board 
and classified as exempt.
RESULTS
Patient Characteristics and Presentation
Between July 2012 and December 2013, 23,809 patients presented with acute STEMI, 
including 18,267 patients who presented directly to a PCI-capable hospital and 5542 who 
were transferred from hospitals without PCI capability (Table 1). Among patients presenting 
to PCI-capable hospitals, 64% (n=11,765) were transported by EMS providers, while 36% 
(n=6502) arrived by self-transport. The median age of the cohort was 60 years (quartiles 52–
70 years); 29% of patients were women; 11% were black; and 10% were of Latino ethnicity.
The overall median time from symptom onset to FMC was 69 minutes. There were marked 
differences in time from symptom onset to FMC according to mode of arrival to the hospital. 
Patients transported by EMS had a median time of 47 minutes from symptom onset to FMC, 
Jollis et al. Page 4
Circulation. Author manuscript; available in PMC 2017 August 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
while self-transported patients had a median time of 114 minutes (p<0.001). The overall 
rates of cardiac arrest or shock on admission was 8% for both events. For patients presenting 
directly to PCI-capable hospitals, those transported by EMS had significantly greater rates of 
cardiac arrest (10% versus 3%) and shock on admission (11% versus 3%, p<0.001 for both 
comparisons) compared with self-transported patients. Transferred patients had rates of 
cardiac arrest (10%) and shock (8%) that were similar to EMS-transported patients. STEMI 
was apparent on the initial ECG for 98% of patients, and 95% of patients were thought to be 
reperfusion candidates by medical record review. Of eligible patients, 94% were treated with 
reperfusion.
Primary Outcome and Temporal Trends
Comparing aggregate rates across all regions, there were significant but modest increases in 
the percentage of patients meeting guideline goals (time from FMC to device of <90 minutes 
for PCI-capable hospitals versus <120 minutes for PCI non-capable hospitals). The 
proportion of patients presenting directly to a PCI-capable center achieving guideline goals 
increased from 59% to 61% (p=0.005) (Figure 1). The subset of EMS-transported patients 
increased from 50% to 55% (p<0.001), and the subset of transferred patients increased from 
44% to 48% (p=0.002). There was substantial regional variability, and the greatest 
improvements were seen in EMS-transported patients. For the 5 most-improved regions 
among EMS-transported patients (Figure 2a), the proportion of those treated within 90 
minutes increased from 45% to 57%, with an increase from 56% to 76% for the most-
improved region (Region 4) (trend test p<0.001 for both comparisons). For transferred 
patients, the proportion treated within 120 minutes increased from 38% to 50% (trend test 
p<0.001), with the most-improved region (Region 9) increasing from 33% to 56% (trend test 
p=0.16) (Figure 2b). The proportion of patients treated within the guideline-recommended 
time intervals for each of the 16 regions is shown in Supplemental Tables 1a and 1b (EMS 
direct) and Supplemental Tables 2a and 2b (transferred).
Overall in-hospital mortality for the time period was 6.1%, with the highest mortality for 
EMS-transported patients (8.2%) and substantially lower mortality for self-transported 
patients (2.7%) presenting directly to a PCI-capable hospital, and an intermediate level of 
mortality for patients transferred to PCI-capable hospitals (5.5%). These mortality 
differences correlated with higher rates of cardiac arrest and shock among the higher 
mortality subgroups.
Over the course of the intervention, there was no significant change in in-hospital mortality. 
Figure 3 shows 12-month (4 quarters) moving-averages of in-hospital mortality rates over 
time for patients treated in the STEMI Systems Accelerator project hospitals (n=27,537) 
versus those treated in hospitals participating in the AR-G registry separately from this work 
(n=97,283). In the first 4 quarters (2012Q4–2013Q3) average, STEMI Systems Accelerator 
hospitals had mortality rates similar to the national comparator’s rates (in the 6.2% range). 
In the final 4 quarters (2013Q4–2014Q3) average, mortality for STEMI Systems Accelerator 
hospitals fell to 5.8%, while the comparator national hospitals’ mortality rate remained 
unchanged (p=0.053). Baseline clinical characteristics were similar between patients 
admitted to Accelerator hospitals compared with those admitted to non-Accelerator hospitals 
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over this time period, with some exceptions (Supplemental Table 3). Compared with non-
Accelerator hospitals, patients admitted to Accelerator hospitals tended to have fewer 
baseline co-morbidities (history of dyslipidemia, hypertension, or prior revascularization) 
but were more likely to present with cardiogenic shock and cardiac arrest.
We also compared FMC-to-device and door-to-device times (75th percentile) by region for 
baseline quarter (Figure 4). We found that all regions had door-to-device times of <90 
minutes for 75% of patients, while no regions achieved this standard for FMC-to-device time 
at the start of our intervention.
DISCUSSION
This work represents the largest effort to organize STEMI care on a regional basis ever 
attempted in the United States, involving 484 hospitals and 1253 EMS agencies in 16 
regions. We found important opportunities for improvement by focusing on guideline goals 
of FMC to device deployment. With the collaboration and support of a diverse range of 
health care professionals, we were able to implement regional data collection, standardize 
reporting, and coordinate treatment plans over 2 years involving approximately one-quarter 
of all STEMI patients entered into the AR-G during the time period. There was marked 
variability in the time required to implement regionally agreed-upon plans. Despite this 
variability, we saw modest but significant improvements in guideline-mandated treatment 
times for the entire cohort and marked improvement in select regions. Notably, temporal 
trends in hospital mortality suggested favorable effects for this broad and intensive quality-
improvement intervention. We expect these trends to continue to improve as the regional 
protocols are implemented on a more complete basis and become embedded as standards of 
care for all hospitals and EMS agencies within a region.
The systems organized in the STEMI Systems Accelerator project differ significantly from 
previously reported individualized STEMI systems—such as those organized by the 
Minneapolis Heart Institute, Prairie Heart Institute, Geisinger Health System, and Mayo 
Clinic—in that these reports generally involve a few primary PCI hospitals within a single 
health care network.15–18 Our hypothesis was that standards of care could be more readily 
changed if the majority of PCI-capable facilities and interventional cardiologists in a region 
could agree to a common plan, thus allowing EMS providers to diagnose and treat patients 
in an expedited fashion without concern or modification according to the receiving facility 
or cardiologist. This work is also unique in that it is the first published intervention to rely 
on Mission: Lifeline™ regional reports, designed according to national guidelines, 
representing aggregated data from the AR-G. These reports include process measures and 
times important to STEMI reperfusion (FMC starting at paramedic or first hospital arrival to 
hospital discharge) according to regional averages and hospital-specific performance.19 
Hospital identifiers were letter-coded and only provided to the individuals working within 
those hospitals.
While much of our effort involved recruiting hospitals to participate in a common regional 
registry and convincing them to allow their data to be aggregated in regional reports, this 
effort in recruiting hospital participation appeared highly fruitful. As a result of these 
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reports, we were able to identify opportunities for systematic improvement using objective 
data and ultimately convince health care systems and providers to modify protocols and 
improve care. The Mission: Lifeline™ reports and systems are currently being implemented 
in many other regions and states, including North Carolina, Mississippi, South Dakota, and 
Dallas, Texas.20
Of particular note is our focus on the 2006 guidelines standard of “first medical contact to 
device” rather than the Center for Medicare and Medicaid Services reported “door to 
balloon” measurement reflective of older standards.2 In our project and as nationally 
reported, the majority of PCI-capable hospitals achieve door-to-device times of <90 minutes. 
As illustrated in Figure 4, for our 16 regions in the baseline period of data collection, all 
regions had door-to-device times of <90 minutes for 75% of patients, while no regions 
achieved this standard for FMC to device. As shown, patients can still have lengthy delays in 
care not identified by the door-to-device metric that does not account for the time between 
patient presentation and hospital arrival. These delays are particularly notable for transferred 
patients. Thus, we believe that a reliance on the door-to-device metric leads to missed 
opportunities for improved care. The remaining delays in STEMI reperfusion identified by 
these data and national registries indicate that FMC should become the focus of national 
quality metrics and efforts. A reliance on the door-to-balloon metric rather than FMC to 
device could explain the relative lack of improvement in outcomes identified by efforts that 
ignore pre-hospital care.21 Findings that fail to identify benefit for faster treatment run 
counter to clinical experience and clinical trial data that indicate the importance of timely 
reperfusion in reducing morbidity and mortality for STEMI patients.22–26
In addition to our overall findings, we present treatment times for each of the 16 
participating regions, as well as the top 5 performing regions for both EMS direct and 
transferred patients. These data have important implications. While the overall results were 
modest, we found significant variability between regions, including those that did not 
improve at all. The overall findings and the variability in improvement was primarily related 
to the speed with which regions could implement effective EMS and hospital transfer 
protocols. A large portion of this delay was related to the time required to persuade the 
majority of regional hospitals to participate in AR-G in shared reporting, execution of 
contracts, and initiation of data collection. This highlights the challenge of pursuing such a 
large scale implementation over a relatively short time period. Nevertheless, the results from 
the most-improved regions indicate that it is possible to rapidly and substantially improve 
reperfusion times within some regions according to our approach. With only 16 regions to 
compare, we cannot reliably identify those regional factors associated with the greatest 
improvement among a myriad of local socioeconomic and political factors that are unique to 
each region. Based upon our experience, we believe the regions most able to improve 
treatment times had common characteristics, including EMS leadership concentrated to a 
few dominant agencies and active daily engagement by a dedicated regional coordinator 
charged with implementing systematic improvements within every hospital and EMS agency 
in the region.
Most efforts to improve STEMI reperfusion times, including this work, have focused on the 
time period from when the patient enters the medical system to the provision of primary PCI 
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or fibrinolysis. At the same time, registries have indicated that the median time from 
symptom onset to presentation has remained in the 2-hour range for at least 2 decades.27,28 
An important observation from our study is that symptom duration for patients presenting to 
EMS was markedly shorter (47 minutes from symptom onset until paramedic arrival versus 
114 minutes for self-transported patients who presented to EDs). This finding identifies an 
opportunity to achieve remarkably shorter total ischemic time (symptom onset to 
reperfusion) and also allows modest improvements in time to result in major improvement in 
salvage (and survival) since these patients are on the “steep part” of the curve describing the 
association of time and mortality. Emergency dispatch programs that encourage patients to 
call 911 for persistent symptoms of potential heart attack, direct ECG-capable providers to 
chest pain calls, and enable paramedics to diagnose STEMI and directly activate 
catheterization laboratories are best suited to markedly decrease the time from symptom 
onset to reperfusion. Our findings of greater illness severity and higher mortality correspond 
with prior work.29 We conjecture that more severe symptoms are likely associated with 
greater illness severity, which triggers patients and families to dispatch emergency medical 
care. Patients who self-transport to the hospital and experience cardiac arrest are much less 
likely to survive or be entered in the AR-G registry compared with those transported by 
EMS.
For ideal patients with recognizable symptoms who receive diagnostic ECGs, and have local 
access to PCI-capable facilities, total ischemic time can potentially be reduced to <2 hours, 
allowing for treatment during the earliest phases of MI when patients are postulated to 
receive the most benefit.23 Such coordinated care is reflected by short ED dwell times as 
patients can proceed from the ambulance to waiting catheterization laboratories with 
successful pre-activation. The potential benefit of such coordination is further supported by 
the observation that shorter ED dwell time is highly associated with lower mortality 
(Supplemental Figure 2). Stratifying EMS-transported patients according to ED dwell time, 
in-hospital mortality was 3.6% for patients with dwell times <30 minutes, 7.0% for dwell 
times of 30 to 45 minutes, and 10.8% for dwell times over 45 minutes. We also found that a 
greater proportion of patients met ED dwell times of ≤20 minutes over the course of the 
study (Supplemental Figure 3). While this comparison of ED time and mortality has great 
potential for confounding according to additional time spent treating patients who suffer life-
threatening events in the ED, the relationship also suggests that processes associated with a 
shorter delay in the ED, such as pre-hospital lab activation by paramedics, may improve 
outcomes. With more than 1700 hospitals performing coronary interventions and up to 90% 
of the U.S. population living within a 60-minute drive time, abbreviated ED dwell times and 
timely intervention should be achievable for the majority of patients transported by 
paramedics.7–10
Limitations
There are limitations worth noting, the first of which involves the observational nature of 
measurements. For an intervention like this, the relationship between our efforts and 
treatment times and mortality is highly subject to confounding. Our finding that Accelerator 
hospitals experienced a trend toward a reduction in unadjusted mortality in the final 4 
quarters (despite similar baseline clinical characteristics) represents post-hoc analyses that 
Jollis et al. Page 8
Circulation. Author manuscript; available in PMC 2017 August 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
provide limited support to the potential for lower mortality in Accelerator regions compared 
with hospitals participating in the AR-G registry at the same time. Furthermore, other 
quality-improvement efforts being conducted by participating EMS agencies and hospitals 
may have contributed to improved treatment times. As the AR-G was regionally expanded to 
institutions and patients who previously would not have been included, treatment times and 
outcomes had the potential to change independent of our intervention if such patients faced 
longer delays compared with patients enrolled in prior quarters.25 Similarly, the global 
nature of our intervention should be considered when comparing these findings to outcomes 
for patients treated in hospitals participating in the AR-G that were not part of this project. 
The approximately 800 hospitals participating in the registry represent a subset of more than 
1700 performing PCI, and their participation possibly indicates greater focus on quality, 
timely treatment, and ultimately better outcomes compared with the universe of hospitals 
performing primary PCI. With such potential for confounding, randomized trials and 
observational registries should serve as the basis for providing timely reperfusion, rather 
than findings from a rapidly expanding regional effort. Finally, despite the large number of 
patients in this study, measuring reperfusion times over 2 years may still be underpowered to 
show the true impact of the intervention, since continual improvement may continue to 
occur in the future.
CONCLUSIONS
This Mission: Lifeline™ STEMI Systems Accelerator Regional Systems of Care 
Demonstration Project represents the largest effort to date in the United States to organize 
treatment for STEMI on a regional basis, involving 484 hospitals, 1253 EMS agencies, and 
many thousands of health care professionals. By focusing on FMC-to-device time, regional 
consensus treatment protocols, and common data collection, we observed a significant 
increase in the proportion of patients treated within guideline goals. The speed with which 
systems could be implemented varied greatly by region, and the improvements demonstrated 
by our data, while modest, suggest the potential for reductions in total ischemic time. 
Corresponding with the fullest implementation of the intervention, we began to observe 
trends toward lower in-hospital mortality compared with national data toward the end of our 
measurement period.
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Clinical Perspective
What is new?
• This work represents the largest effort ever attempted in the United 
States to organize ST-segment elevation myocardial infarction (STEMI) 
care across multiple regions.
• The work involved 23,809 patients treated at 484 hospitals and 1253 
emergency medical services (EMS) agencies in 16 regions, including 
New York City, Atlanta, Houston, and St. Louis, or roughly one in four 
patients entered into the NCDR’s ACTION Registry® during the 18 
months of measurement.
What are the clinical implications?
• Supported by thousands of colleagues and American Heart Association 
quality personnel, we were able to organize regional leadership and 
coordinate treatment plans that spanned the majority of EMS providers, 
emergency departments, and cardiac catheterization laboratories within 
each region.
• These primary results show modest but significant improvements in 
treatment times, with marked improvement in the five top-performing 
regions.
• These findings support continued efforts to implement regional STEMI 
networks.
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Figure 1. 
Percent of patients meeting guideline goal for FMC-to-device time by quarter. Numbers 
below each bar represent the total number of patients for each transportation modality for 
that quarter.
Direct = all patients presenting directly to PCI-capable hospitals; EMS = patients presenting 
to PCI-capable hospitals by EMS transport; FMC = first medical contact; Transfer = patients 
transferred to PCI-capable hospitals; Q = quarter.
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Figure 2. 
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Percentage of EMS-transported patients meeting guideline goals for FMC-to-device time by 
quarter, 5 most-improved regions for direct EMS patients (a) and transferred patients (b)
EMS = emergency medical services’ FMC = first medical contact; Q = quarter.
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Figure 3. 
Rolling 12-month (4 quarters) moving-average of in-hospital mortality comparing AR-G 
patients treated in STEMI Systems Accelerator hospitals (Accelerator) versus hospitals not 
participating in the project (National)
ACTION Registry®-Get With The Guidelines™; Q= quarter.
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Figure 4. 
FMC and door-to-device times by region, 75th percentile for baseline quarter
FMC = first medical contact.
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Table 1
Patient Characteristics, 7 Quarters (2012Q3 to 2014Q1)
Characteristic
Direct presenter, EMS 
transport (N=11,765)
Direct presenter, self 
transport (N=6502)
Transferred (N=5542) Overall (N=23809)
Age (years)
 N 11765 6502 5542 23809
 Median 62.0 59.0 60.0 60.0
 Q1–Q3 53.0–72.0 51.0–68.0 52.0–69.0 52.0–70.0
Sex, n (%)
 Male 8002 (68.0%) 4811 (74.0%) 4021 (72.6%) 16834 (70.7%)
 Female 3763 (32.0%) 1691 (26.0%) 1521 (27.4%) 6975 (29.3%)
Race, n (%)
 White 9510 (80.8%) 5475 (84.2%) 4615 (83.3%) 19600 (82.3%)
 Black 1456 (12.4%) 589 (9.1%) 508 (9.2%) 2553 (10.7%)
 Other 799 (6.8%) 438 (6.7%) 419 (7.6%) 1656 (7.0%)
Latino ethnicity, n (%) 1181/11737 (10.1 %) 771/6477 (11.9%) 413/5532 (7.5%) 2365/23746 (10.0%)
Insurance, n (%)
 Private/HMO 6133/9874 (62.1%) 3867/5415 (71.4%) 3109/4651 (66.9%) 13109/19940 (65.7%)
 Medicaid 1278/9874 (12.9%) 481/5415 (8.9%) 536/4651 (11.5%) 2295/ 19940 (11.5%)
 None 1891 (16.1%) 1087 (16.7%) 891 (16.1%) 3869 (16.3%)
 Other 2608 (22.2%) 1112 (17.1%) 1058 (19.1%) 4778 (20.1%)
Prior myocardial infarction, n (%) 1536/8025 (19.1%) 699/4498 (15.5%) 580/3640 (15.9%) 2815/16163 (17.4%)
Prior heart failure, n (%) 490/8021 (6.1%) 141/4495 (3.1%) 157/3640 (4.3%) 788/ 16156 (4.9%)
Prior PCI, n (%) 1636/8025 (20.4%) 809/4498 (18.0%) 618/ 3641 (17.0%) 3063/16164 (19.0%)
Prior coronary bypass surgery, n 
(%)
442/8021 (5.5%) 243/4499 (5.4%) 210/3638 (5.8%) 895/16158 (5.5%)
Diabetes mellitus, n (%) 3160/11757 (26.9%) 1756/6501 (27.0%) 1412/ 5537 (25.5%) 6328/23795 (26.6%)
Symptom onset to FMC (minutes)
 N 10,432 5587 4833 20,852
 Median 47.0 114.0 89.0 69.0
 Q1–Q3 22.0–116.0 56.0–272.0 47.0–200.0 32.0–172.0
Shock on presentation, n (%) 1313/11754 (11.2%) 215/6498 (3.3%) 465/5533 (8.4%) 1993/23785 (8.4%)
Cardiac arrest, n (%) 1227/11703 (10.5%) 169/6455 (2.6%) 531/5515 (9.6%) 1927/23673 (8.1%)
Heart failure on presentation, n (%) 906/11756 (7.7%) 351/6497 (5.4%) 417/5534 (7.5%) 1674/23787 (7.0%)
Reperfusion candidate, n (%) 11248/11751 (95.7%) 6180/6497 (95.1%) 5234/5535 (94.6%) 22662/23783 (95.3 %)
Heart rate on presentation (bpm)
 N 11,737 6485 5529 23,751
 Median 78.0 81.0 79.0 80.0
 Q1–Q3 64.0–93.0 69.0–95.0 66.0–94.0 66.0–94.0
Systolic BP (mmHg)
 N 11,734 6483 5526 23,743
 Median 134.0 150.0 142.0 140.0
 Q1–Q3 111.0–155.0 130.0–171.0 122.0–162.0 119.0–161.0
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Characteristic
Direct presenter, EMS 
transport (N=11,765)
Direct presenter, self 
transport (N=6502)
Transferred (N=5542) Overall (N=23809)
STEMI first diagnosed, n (%)
 First ECG 11459/11693(98.0%) 6328/6444 (98.2%) 5415/5497 (98.5%) 23202/23634 (98.2 %)
 Subsequent 234/11693 (2.0%) 116/6444 (1.8%) 82/5497 (1.5%) 432/23634 (1.8%)
Procedures during hospitalization, n 
(%)
 PCI 10579/11762 (89.9%) 5883 (90.5%) 4890 (88.2%) 21352 (89.7%)
 Coronary bypass surgery 428 (3.6%) 266 (4.1%) 314 (5.7%) 1008 (4.2%)
Complications, n (%)
 In-hospital death 961 (8.2%) 175 (2.7%) 306 (5.5%) 1442 (6.1%)
 Stroke 92 (0.8%) 43 (0.7%) 51 (0.9%) 186 (0.8%)
 Hemorrhagic stroke 13 (0.1%) 7 (0.1%) 9 (0.2%) 29 (0.1/185 (15.7%)
 Cardiogenic shock 1095/11747 (9.3%) 355/6499 (5.5%) 421/5539 (7.6%) 1871/23785 (7.9%)
 Congestive heart failure 826/11748 (7.0%) 317/6497 (4.9%) 345/5537 (6.2%) 1488/23782 (6.3 %)
 Major bleeding 560/11749 (4.8%) 227/6496 (3.5%) 233/5538 (4.2%) 1020/23783 (4.3%)
 Reinfarction 112/11749 (1.0%) 53/6497 (0.8%) 44/5538 (0.8%) 209/23784 (0.9%)
Not treated, n (%) 751 (6.4%) 385 (5.9%) 338 (6.1%) 1474 (6.2%)
ED dwell time (minutes), n (%)
 n 10234 5855 2329 18418
 ≤20 2560 (25.0%) 253 (4.3%) 503 (21.6%) 3316 (18%)
 >20 to ≤30 2045 (20.0%) 794 (13.6%) 256 (11.0%) 3095 (16.8%)
 >30 to ≤45 2575 (25.2%) 1474 (25.2%) 850 (36.5%) 4899 (26.6%)
 >45 3054 (29.8%) 3334 (56.9%) 720 (30.9%) 7108 (38.6%)
ED = emergency department; EMS = emergency medical services; HMO = health maintenance organization; PCI = percutaneous coronary 
intervention; STEMI = ST-segment elevation myocardial infarction
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